Armando Santoro

Summary

Affiliation: Istituto Clinico Humanitas
Country: Italy

Publications

  1. ncbi request reprint Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study
    Hector Soto Parra
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni, 56 Rozzano Milan 20089, Italy
    Invest New Drugs 25:57-62. 2007
  2. pmc Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients
    Marta Scorsetti
    Istituto Clinico Humanitas IRCCS, Radiation Oncology Dept, Milan Rozzano, Italy
    Radiat Oncol 5:93. 2010
  3. pmc Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc
    Marta Scorsetti
    Department of Radiation Oncology, IRCCS Istituto Clinico Humanitas, Milano Rozzano, Italy
    Radiat Oncol 5:94. 2010
  4. pmc Oral ulcer as an exclusive sign of gastric cancer: report of a rare case
    Piergiuseppe Colombo
    Department of Pathology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    BMC Cancer 5:117. 2005
  5. ncbi request reprint Lymphomas
    Armando Santoro
    Department of Medical Oncology and Hematology, Instituto Clinico Humanitas, Rozzano Milano, Italy
    Cancer Chemother Biol Response Modif 21:399-428. 2003
  6. ncbi request reprint Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
    A Santoro
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Ann Oncol 15:33-7. 2004
  7. doi request reprint Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program
    Armando Santoro
    Istituto Clinico Humanitas, Rozzano, Italy
    J Thorac Oncol 3:756-63. 2008
  8. ncbi request reprint Lymphomas
    Armando Santoro
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Via Manzoni 56, 20089 Milan, Italy
    Cancer Chemother Biol Response Modif 20:391-418. 2002
  9. ncbi request reprint Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
    Armando Santoro
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Haematologica 92:35-41. 2007
  10. ncbi request reprint Lymphomas
    Armando Santoro
    Department of Medical Oncology and Hematology, Istituto Clnico Humanitas, Milano, Italy
    Cancer Chemother Biol Response Modif 22:391-9. 2005

Detail Information

Publications138 found, 100 shown here

  1. ncbi request reprint Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study
    Hector Soto Parra
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni, 56 Rozzano Milan 20089, Italy
    Invest New Drugs 25:57-62. 2007
    ..The 3-week schedule is generally preferred because it enables better treatment compliance. To improve DI and compliance further, we delivered gemcitabine plus cisplatin over 4 days every 21 days...
  2. pmc Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients
    Marta Scorsetti
    Istituto Clinico Humanitas IRCCS, Radiation Oncology Dept, Milan Rozzano, Italy
    Radiat Oncol 5:93. 2010
    ..To report about early clinical experience in radiation treatment of head and neck cancer of different sites and histology by volumetric modulated arcs with the RapidArc technology...
  3. pmc Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc
    Marta Scorsetti
    Department of Radiation Oncology, IRCCS Istituto Clinico Humanitas, Milano Rozzano, Italy
    Radiat Oncol 5:94. 2010
    ..To report acute toxicity, initial outcome results and planning therapeutic parameters in radiation treatment of advanced lung cancer (stage III) with volumetric modulated arcs using RapidArc (RA)...
  4. pmc Oral ulcer as an exclusive sign of gastric cancer: report of a rare case
    Piergiuseppe Colombo
    Department of Pathology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    BMC Cancer 5:117. 2005
    ..Oral metastatic lesions have been described in various cancers, particularly lung, breast and kidney carcinoma...
  5. ncbi request reprint Lymphomas
    Armando Santoro
    Department of Medical Oncology and Hematology, Instituto Clinico Humanitas, Rozzano Milano, Italy
    Cancer Chemother Biol Response Modif 21:399-428. 2003
  6. ncbi request reprint Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
    A Santoro
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Ann Oncol 15:33-7. 2004
    ..Therefore, we aimed to assess the antitumor activity and tolerability of gefitinib in a series of patients with previously treated, advanced NSCLC, as a part of a compassionate use program...
  7. doi request reprint Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program
    Armando Santoro
    Istituto Clinico Humanitas, Rozzano, Italy
    J Thorac Oncol 3:756-63. 2008
    ..This manuscript reports the safety and efficacy data from the nonrandomized open-label study in chemonaïve patients receiving pemetrexed plus platinum under the EAP...
  8. ncbi request reprint Lymphomas
    Armando Santoro
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Via Manzoni 56, 20089 Milan, Italy
    Cancer Chemother Biol Response Modif 20:391-418. 2002
  9. ncbi request reprint Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
    Armando Santoro
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Haematologica 92:35-41. 2007
    ..Results of a new induction regimen are reported in terms of response rates, toxicity, and stem cell mobilization...
  10. ncbi request reprint Lymphomas
    Armando Santoro
    Department of Medical Oncology and Hematology, Istituto Clnico Humanitas, Milano, Italy
    Cancer Chemother Biol Response Modif 22:391-9. 2005
  11. ncbi request reprint Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study
    A Santoro
    Istituto Clinico Humanitas, Rozzano Milano, Italy
    J Clin Oncol 18:2615-9. 2000
    ..To explore the use of gemcitabine for the treatment of patients with relapsing or refractory Hodgkin's disease...
  12. ncbi request reprint Dose-escalation of CHOP in non-Hodgkin's lymphoma
    A Santoro
    Division of Medical Oncology, Istituto Nazionale Tumori, Milano, Italy
    Ann Oncol 10:519-25. 1999
    ..In order to determine the maximum tolerable dose of an intensified CHOP regimen, a dose-escalation study of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with non-Hodgkin's lymphoma (NHL) was started...
  13. ncbi request reprint CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients
    Elisabetta Todisco
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milano, Italy
    Eur J Haematol 78:111-6. 2007
    ..Our data suggest that G-CSF administration can be safely optimized, used only for patients infused with a suboptimal CD34(+) cell dose...
  14. ncbi request reprint Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study
    Luca Castagna
    Department of Hematology and Medical Oncology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Am J Hematol 82:122-7. 2007
    ..Tandem HDCT is feasible and effective in patients with relapsed or refractory HL...
  15. doi request reprint Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy
    Luca Castagna
    Oncology and Haematology Department, Istituto Clinico Humanitas, Rozzano MI, Italy
    Br J Haematol 145:369-72. 2009
    ..The 2-year progression-free survival was 93% vs. 10% for patients with negative and positive PET2, respectively (P < 0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients...
  16. ncbi request reprint Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
    Giuseppe Luigi Banna
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Biol Blood Marrow Transplant 12:1085-91. 2006
    ..Earlier HDCT administration followed by residual surgery should be considered for further investigation...
  17. doi request reprint Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
    Paolo A Zucali
    Department of Medical Oncology and Hematology, Humanitas Clinical Institute of Rozzano, Milan, Italy
    Cancer 112:1555-61. 2008
    ..Gemcitabine and vinorelbine have shown activity in the first-line setting. The objective of this study was to evaluate the activity and toxicity of the gemcitabine-vinorelbine combination in pemetrexed-pretreated patients with MPM...
  18. doi request reprint Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
    Nicola Personeni
    Department of Oncology Hematology, Humanitas Cancer Center, IRCCS, Rozzano, Italy
    J Hepatol 57:101-7. 2012
    ..We investigated the prognostic usefulness of a decrease in serum alpha-fetoprotein (AFP) and compared it to RECIST...
  19. doi request reprint Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
    Nicola Personeni
    Department of Oncology Hematology, Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, MI, Italy
    J Cancer Res Clin Oncol 139:1179-87. 2013
    ..However, the determinants of sorafenib sensitivity in vivo remain largely unknown...
  20. doi request reprint Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases
    Elena Miranda
    Molecular Genetics Laboratory, Humanitas Clinical and Research Center, Milan, Italy
    Cancer 119:266-76. 2013
    ..The objective of this study was to evaluate the presence of molecular heterogeneity during metastatic progression and its potential impact on clinical treatment...
  21. ncbi request reprint Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer
    Elisabetta Campagnoli
    Dipartimento di Oncologia Medica e Ematologia, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, 20089, Rozzano, MI, Italy
    Invest New Drugs 25:559-64. 2007
    ..Non-haematological toxicity was mild. This schedule of cisplatin and vinorelbine treatment showed a good toxicity profile and an efficacy similar to other standard regimens. Oral vinorelbine could be administered safely at home on day 5...
  22. doi request reprint Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin
    Paolo Andrea Zucali
    Department of Oncology, Biostatistics Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    Clin Cancer Res 17:2581-90. 2011
    ....
  23. ncbi request reprint Assessment of tumor response in malignant pleural mesothelioma
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    Cancer Treat Rev 33:533-41. 2007
    ..New serum markers such as osteopontin and mesothelin-related proteins are under evaluation and in the future might play a role in assessing the response of MPM to treatment...
  24. ncbi request reprint The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study
    Carlo Carnaghi
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano Milano, Italy
    Invest New Drugs 25:479-85. 2007
    ..Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached...
  25. doi request reprint Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors
    Matteo Simonelli
    Oncology and Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
    Eur J Cancer 49:989-98. 2013
    ....
  26. pmc Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments
    Marta Scorsetti
    Radiotherapy and Radiosurgery, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Milano, Italy
    Radiat Oncol 7:145. 2012
    ..To report results in terms of feasibility and early toxicity of hypofractionated simultaneous integrated boost (SIB) approach with Volumetric Modulated Arc Therapy (VMAT) as adjuvant treatment after breast-conserving surgery...
  27. doi request reprint A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial
    Maurizio Infante
    Thoracic Surgery Department, Istituto Clinico Humanitas, Milan, Italy
    Am J Respir Crit Care Med 180:445-53. 2009
    ..Screening for lung cancer with modern imaging technology may decrease lung cancer mortality, but encouraging results have only been obtained in uncontrolled studies...
  28. ncbi request reprint Short schedule of cisplatin and vinorelbine: a dose-finding study in non-small-cell lung cancer
    Paolo Andrea Zucali
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Oncology 71:229-36. 2006
    ..A dose-finding study of a new cisplatin/vinorelbine schedule was done to increase activity of the combination, and improve compliance of non-small-cell lung cancer PATIENTS...
  29. doi request reprint Future developments in the management of malignant pleural mesothelioma
    Paolo Andrea Zucali
    Department of Medical Oncology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Expert Rev Anticancer Ther 9:453-67. 2009
    ..The principal goals of this review are to summarize the improvements in the management of MPM that have been achieved recently and to outline the therapeutic approaches in development...
  30. ncbi request reprint Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion
    Elisabetta Todisco
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Eur J Haematol 78:322-9. 2007
    ..We analysed the feasibility and efficacy of allogeneic stem cell transplantation (allo-SCT) with reduced-intensity conditioning (RIC) in patients with refractory or progressive Hodgkin's disease (HD) after high-dose chemotherapy (HDCT)...
  31. ncbi request reprint Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy
    Carlo Carnaghi
    Department of Oncology, IRCCS Humanitas, Rozzano Milano, Italy
    Nucl Med Rev Cent East Eur 10:12-5. 2007
    ..Our aim was to assess the value of this imaging modality in the selection of patients with colorectal liver metastasis for surgery following adjuvant chemotherapy...
  32. ncbi request reprint Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients
    Massimo Magagnoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Am J Hematol 81:1-4. 2006
    ..Four episodes of bleeding occurred, with each of these individuals having a normal INR but a platelet count below 50,000/dL. Minidose warfarin is effective and safe to use for preventing thrombotic events in this setting of patients...
  33. doi request reprint The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer
    Francesco Sclafani
    Medical Oncology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano, Italy
    J Thorac Cardiovasc Surg 145:97-103. 2013
    ..Our objective was to investigate the role of clinicopathologic factors as predictors of outcome after complete pulmonary resection for metastatic colorectal cancer...
  34. pmc Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience
    Flavio Tancioni
    Department of Neurosurgery, Istituto Clinico Humanitas, Rozzano, Italy
    Eur Spine J 21:S146-8. 2012
    ..To identify potential prognostic factors predicting functional outcome and survival after surgery followed by radiotherapy for metastatic spinal cord compression due to solid tumors...
  35. ncbi request reprint Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study
    Marta Scorsetti
    Department of Radiation Oncology, Istituto Clinico Humanitas, Rozzano, Italy
    Int J Radiat Oncol Biol Phys 77:942-9. 2010
    ..A planning study was performed to evaluate RapidArc (RA), a volumetric modulated arc technique, on malignant pleural mesothelioma. The benchmark was conventional fixed-field intensity-modulated radiotherapy (IMRT)...
  36. doi request reprint Multimodal approach to the management of metastatic epidural spinal cord compression (MESCC) due to solid tumors
    Flavio Tancioni
    Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy
    Int J Radiat Oncol Biol Phys 78:1467-73. 2010
    ..To assess the impact of a multidisciplinary approach for treatment of patients with metastatic epidural spinal cord compression in terms of feasibility, local control, and survival...
  37. ncbi request reprint Primary mediastinal B-cell lymphoma with sclerosis: report of 11 cases treated with intensified-CHOP plus radiotherapy
    Licia Siracusano
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Am J Hematol 78:312-3. 2005
    ..After a median follow up of 30 months, all patients but one are in continuous complete remission (CR), and overall survival is 100%...
  38. doi request reprint Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma
    Luca Castagna
    Hematology Oncology Department, Istituto Clinico Humanitas, Rozzano, Milano, Italy
    Biol Blood Marrow Transplant 15:432-8. 2009
    ..The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD...
  39. pmc Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications
    S Viviani
    Division of Medical Oncology A, Istituto Nazionale Tumori, Milano, Italy
    Br J Cancer 77:992-7. 1998
    ....
  40. doi request reprint Surgery followed by radiotherapy for the treatment of metastatic epidural spinal cord compression from breast cancer
    Flavio Tancioni
    Department of Neuro Surgery, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
    Spine (Phila Pa 1976) 36:E1352-9. 2011
    ..Retrospective analysis of breast cancer patients with metastatic epidural spinal cord compression (MESCC) undergoing surgery and radiation therapy...
  41. doi request reprint Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer
    Giuseppe Gullo
    Oncology and Hematology Unit, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, Milan, Italy
    Invest New Drugs 27:179-83. 2009
    ..If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC...
  42. ncbi request reprint Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications
    Giovanna Masci
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano, Milano, Italy
    Support Care Cancer 14:1141-6. 2006
    ..This study is a retrospective investigation of our experience using the Vygon catheter as a long-term CVC in patients with malignancy...
  43. doi request reprint Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability
    Barbara Sarina
    Hematology Department, Istituto Clinico Humanitas, Milano, Italy
    Blood 115:3671-7. 2010
    ..001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed autoSCT, indicating a survival benefit for patients having a donor...
  44. ncbi request reprint Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution
    Massimo Magagnoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano Milan, Italy
    Am J Hematol 73:267-72. 2003
    ..HDT supported by PBSC is a feasible procedure in selected elderly patients, and an age of more than 60 years should not be considered a contraindication for HDT...
  45. ncbi request reprint Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up
    Annarita Destro
    Molecular Genetics Laboratory, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Lung Cancer 59:369-76. 2008
    ..This result suggests the need to select homogeneously treated and staged patients with MPM to address whether their methylation profile may impact on patient's survival...
  46. pmc Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib
    Giovanni Abbadessa
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, 20089 Rozzano, Milan, Italy
    World J Gastroenterol 17:2450-3. 2011
    ..This report supports the feasibility of dose adjustments to allow prolonged administration of sorafenib, and highlights the need for new imaging criteria for a more appropriate characterization of response in HCC...
  47. ncbi request reprint Weekly non-pegylated liposomal doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer
    Giovanna Masci
    Oncology and Hematology Unit, Humanitas Cancer Center, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Anticancer Res 33:4603-9. 2013
    ....
  48. doi request reprint Early surgical experience with minimally invasive percutaneous approach for patients with metastatic epidural spinal cord compression (MESCC) to poor prognoses
    Flavio Tancioni
    Department of Neurosurgery, Istituto Clinico Humanitas Cancer Center, Milan, Italy
    Ann Surg Oncol 19:294-300. 2012
    ....
  49. doi request reprint Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors
    Francesco Sclafani
    Medical Oncology and Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano MI, Italy
    Tumori 97:620-8. 2011
    ..Immunohistochemistry (IHC) was reported as a reliable method for the detection of SSTRs with theoretically superior sensitivity over SRS...
  50. ncbi request reprint High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study
    Alexia Bertuzzi
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    J Clin Oncol 20:2181-8. 2002
    ..In this phase II study, we explored a high-dose chemotherapy (HD-CT) approach and analyzed the clinical significance of fusion transcripts detection...
  51. doi request reprint Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases
    Mario Bignardi
    Radiation Oncology Department, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
    Int J Radiat Oncol Biol Phys 81:831-8. 2011
    ..We report the medium-term clinical outcome of hypofractionated stereotactic body radiotherapy (SBRT) in a series of patients with either a solitary metastasis or oligometastases from different tumors to abdominal lymph nodes...
  52. ncbi request reprint Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: analysis of its use in 427 cancer patients
    Massimo Magagnoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Anticancer Res 25:3143-7. 2005
    ....
  53. ncbi request reprint Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    J Clin Oncol 24:4587-93. 2006
    ..There is growing evidence that therapy-induced changes in tumor [(18)F]fluorodeoxyglucose (FDG) uptake as measured by positron emission tomography (PET) may predict response and patient outcome early in the course of treatment...
  54. doi request reprint Rectal squamous cell carcinoma treated with chemoradiotherapy: report of six cases
    Maria Chiara Tronconi
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano, Milan, Italy
    Int J Colorectal Dis 25:1435-9. 2010
    ..A retrospective analysis of these cases was performed in order to evaluate the role of chemoradiotherapy as an alternative to surgery...
  55. pmc Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
    H S Parra
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via A Manzoni 56, Rozzano, Milan 20089, Italy
    Br J Cancer 91:208-12. 2004
    ..Gefitinib demonstrated promising clinical activity in this group of patients with NSCLC. These results have also shown that EGFR expression is not a significant predictive factor for response to gefitinib...
  56. ncbi request reprint Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
    P A Zucali
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Ann Oncol 19:1605-12. 2008
    ..However, resistance mechanisms are not well understood. We evaluated several potential biological markers of intrinsic EGFR-TKIs-resistance in NSCLC...
  57. ncbi request reprint The present and the future landscape of treatment of advanced hepatocellular carcinoma
    Lorenza Rimassa
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Dig Liver Dis 42:S273-80. 2010
    ..In this review, we will summarize the data concerning the present standard treatment for advanced HCC and discuss the newest, most promising clinical research that may affect the future treatment of this disease...
  58. doi request reprint Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review
    Marta Scorsetti
    Department of Radiotherapy and Radiosurgery, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Tumori 98:67e-71e. 2012
    ..We discuss the case comparing our approach with other experiences reported in the literature...
  59. doi request reprint Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy
    Armando Santoro
    Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy
    Eur J Cancer 46:2746-52. 2010
    ..Preclinical antitumour activity was observed even at low doses. We evaluated the activity and safety of low-dose NGR-hTNF in colorectal cancer (CRC) patients failing standard therapies...
  60. doi request reprint Vertebroplasty for pain relief and spinal stabilization in multiple myeloma
    Flavio Tancioni
    Department of Neurosurgery, Instituto Clinico Humanitas, Milan, Italy
    Neurol Sci 31:151-7. 2010
    ....
  61. ncbi request reprint What is the best option to cure patients with resistant/relapsing Hodgkin's disease?
    Massimo Magagnoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Curr Stem Cell Res Ther 1:419-24. 2006
    ..In this review we analyzed the results of the most important salvage chemotherapy combinations as well as allogeneic transplantations to clarify the optimal treatment options for patients with resistant/relapsing HD...
  62. doi request reprint Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma
    Vanesa Gregorc
    Department of Oncology, Istituto Scientifico San Raffaele, Universita Vita Salute San Raffaele, Milan, Italy
    J Clin Oncol 28:2604-11. 2010
    ..Currently, there are no standard options for patients with MPM who are failing a front-line pemetrexed-based regimen. We explored safety and efficacy of NGR-hTNF in this setting...
  63. doi request reprint EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?
    Giovanna Finocchiaro
    Istituto Clinico Humanitas IRCCS, Division of Oncology Hematology, Via Manzoni 56, 20089 Rozzano, Italy 39 02 8224 4097 39 02 8224 4590
    Expert Opin Med Diagn 1:183-91. 2007
    ..There are several mechanisms that have been identified as responsible for intrinsic or acquired resistance. The aim of the present review is to analyze available data in order to identify an optimal paradigm for patient selection...
  64. doi request reprint Retroperitoneal sarcoma: is it time to change the surgical policy?
    Chiara Mussi
    Sarcoma Unit, Surgical Department, Istituto Clinico Humanitas, University of Milan School of Medicine, Rozzano Milan, Italy
    Ann Surg Oncol 18:2136-42. 2011
    ..We analyzed a single-institution series of RPS to provide information useful to surgical decision-making...
  65. ncbi request reprint Percutaneous vertebral augmentation in metastatic disease: state of the art
    Flavio Tancioni
    Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy
    J Support Oncol 9:4-10. 2011
    ....
  66. ncbi request reprint The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas
    Paolo Andrea Zucali
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni, 56 Rozzano, Milan, 20089, Italy
    Invest New Drugs 26:175-81. 2008
    ....
  67. doi request reprint Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer
    Francesco Sclafani
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, IRCCS, Rozzano, Italy
    Chemotherapy 56:203-7. 2010
    ..Moreover, the potential association between anticancer drugs and vascular damage is well known since chemotherapeutics, such as fluoropyrimidines, were introduced into clinical practice...
  68. ncbi request reprint Herpes infections in breast cancer patients treated with adjuvant chemotherapy
    Giovanna Masci
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Milan, Italy
    Oncology 71:164-7. 2006
    ..The aim of this study is to evaluate the incidence of Herpes zoster and simplex infections in this patients setting...
  69. ncbi request reprint Neutropenic enterocolitis: is there a right timing for surgery? Assessment of a clinical case
    Pietro Bagnoli
    Department of Surgical Oncology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Tumori 93:608-10. 2007
    ....
  70. ncbi request reprint Combined systemic and intrathecal chemotherapy plus radiotherapy in testicular lymphoma: a report of two cases
    Massimo Magagnoli
    Departmenti of Medical Oncology and Hematology, Istituto Clinico Humanitas Via Manzoni 56, 20089 Rozzano, Italy
    Haematologica 87:ELT22. 2002
  71. ncbi request reprint Metastasis of hepatocellular carcinoma to the heart: a case report and review of the literature
    Giovanna Masci
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Tumori 90:345-7. 2004
    ..The patient died of progressive hepatic failure six months later. In addition to this case report, a review of the literature on heart involvement from HCC is presented...
  72. ncbi request reprint High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review
    Giuseppe Luigi Banna
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni, 56, 20089 Rozzano, Milano, Italy
    Curr Stem Cell Res Ther 2:65-82. 2007
    ..Well-designed randomized studies and future strategies integrating HDCT with concomitant and/or subsequent anti-tumor therapies targeted against the residual disease might be suggested in clinically and biologically selected patients...
  73. doi request reprint Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas
    Elisa Stroppa
    Department of Medical Oncology and Haematology, Istituto Clinico Humanitas, Via Manzoni 56, Rozzano, Milan, 20089, Italy
    Invest New Drugs 28:834-8. 2010
    ..The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas...
  74. doi request reprint CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study
    Luigi Laghi
    Laboratories of Molecular Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Lancet Oncol 10:877-84. 2009
    ..The aim of this study was to assess the relationship between the density of CD3+ TIL and the postsurgical occurrence of distant-organ metastases in a large series of patients with deeply invading and MSI-typed colorectal cancer...
  75. ncbi request reprint Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Milan, Italy
    J Clin Oncol 24:1443-8. 2006
    ..This multicenter, phase II clinical study was conducted to evaluate the activity of the combination of pemetrexed and carboplatin in patients with malignant pleural mesothelioma (MPM)...
  76. ncbi request reprint Irinotecan and raltitrexed: an active combination in advanced colorectal cancer
    C Carnaghi
    Medical Oncology and Haematology Department, Istituto Clinico Humanitas, Milan, Italy
    Ann Oncol 13:1424-9. 2002
    ..The aim of our phase II trial was to assess the efficacy and tolerability of the combination of irinotecan and raltitrexed in patients with metastatic colorectal cancer untreated with chemotherapy...
  77. ncbi request reprint Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study
    C Tondini
    Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 11:231-3. 2000
    ..It is unclear whether the purine analogs fludarabine (Flu) and cladribine (CdA) are non-resistant...
  78. doi request reprint Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial
    Lorenza Rimassa
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Expert Rev Anticancer Ther 9:739-45. 2009
    ..The SHARP trial has demonstrated that sorafenib is effective in prolonging median survival and time-to-progression in patients with advanced HCC and that it is generally well tolerated with a manageable adverse events profile...
  79. doi request reprint High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid
    Monica Zuradelli
    Dipartimento di Oncologia Medica ed Ematologia, Istituto Clinico Humanitas, Via Manzoni 56, Rozzano, Milan, Italy
    Oncologist 14:548-56. 2009
    ..The primary aim of this study was to establish the actual incidence of hypocalcemia and serum creatinine elevation during treatment with zoledronic acid. Skeletal-related events and side effects were also assessed...
  80. ncbi request reprint Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer
    Lorenza Rimassa
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano MI, Italy
    Breast Cancer Res Treat 77:185-8. 2003
    ..Toxicity was acceptable, however, grade 3-4 neutropenia was not negligible. Our study does not support the development of this combination in advanced breast cancer...
  81. ncbi request reprint Role of computed tomography and [18F] fluorodeoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without elective nodal irradiation
    Giovanni Luca Ceresoli
    Department of Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Tumori 93:88-96. 2007
    ....
  82. ncbi request reprint Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin
    Lorenza Rimassa
    Medical Oncology and Haematology Department, Istituto Clinico Humanitas, Rozzano, MI, Italy
    Tumori 92:285-9. 2006
    ..To assess the activity and tolerability of the combination of mitomycin C and capecitabine in patients with metastatic colorectal cancer after failure of irinotecan and oxaliplatin-containing regimens...
  83. pmc Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study
    P F Conte
    Department of Medical Oncology and Hematology, University of Modena and Reggio Emilia, Italy
    Br J Cancer 93:406-11. 2005
    ..The gemcitabine, epirubicin, taxol regimen is active and well tolerated as PCT for operable breast cancer. This combination allows the administration of full doses of active agents with a low incidence of febrile neutropenia...
  84. ncbi request reprint Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
    Federico Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy
    Lung Cancer 41:227-31. 2003
    ..We report four cases of Brain Metastases (BM) from non-small cell lung cancer (NSCLC) responding to ZD 1839 therapy after standard therapy failure...
  85. ncbi request reprint Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas
    L Castagna
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Bone Marrow Transplant 30:207-14. 2002
    ..Our study confirms that a low intensity conditioning regimen for allogeneic stem cell transplantation is feasible and effective in heavily pretreated patients...
  86. pmc Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients
    Federico Cappuzzo
    Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico, Department of Oncology Hematology, University of Milan School of Medicine, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
    J Clin Oncol 27:1667-74. 2009
    ..To investigate the prognostic role of genomic gain for MET and epidermal growth factor receptor (EGFR) genes in surgically resected non-small-cell lung cancer (NSCLC)...
  87. doi request reprint Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, Milano, Italy
    Breast Cancer Res Treat 126:431-41. 2011
    ....
  88. ncbi request reprint Multidisciplinary treatment of malignant pleural mesothelioma
    Giovanni Luca Ceresoli
    Dipartimento di Oncologia Medica e Ematologia, Istituto Clinico Humanitas IRCCS, Via Manzoni, Rozzano MI, Italy
    Oncologist 12:850-63. 2007
    ..However, currently available treatments still appear to have modest results. Further studies are needed to provide evidence-based recommendations for the treatment of early and advanced stages of this disease...
  89. ncbi request reprint Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer
    Alberto Malesci
    Department of Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Clin Cancer Res 13:3831-9. 2007
    ..Although associated with earlier-stage tumors, MSI has been proposed as an independent predictor of survival. We tested the prognostic value of MSI in a large series of patients diagnosed with colorectal cancer in the last decade...
  90. ncbi request reprint Solitary plasmacytoma of the duodenum
    Massimo Magagnoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Am J Hematol 76:185-6. 2004
  91. doi request reprint Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics
    Monica Zuradelli
    Unit of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Breast Cancer Res Treat 124:251-8. 2010
    ..The possible association of DH for BRCA gene mutations with gastrointestinal tumors is in keeping with previous reports, but needs to be confirmed by further analyses...
  92. doi request reprint Re-irradiation of metastatic spinal cord compression: a feasibility study by volumetric-modulated arc radiotherapy for in-field recurrence creating a dosimetric hole on the central canal
    Pietro Mancosu
    IRCCS Istituto Clinico Humanitas, Radiation Oncology, Via Manzoni 56, 20098 Rozzano, Italy
    Radiother Oncol 94:67-70. 2010
    ..A clinically satisfactory PTV coverage and dose sparing to the spinal cord were obtained. An upcoming trial on patients will provide clinical outcomes...
  93. ncbi request reprint Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?
    Giovanna Masci
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    J Clin Oncol 21:736-9. 2003
    ..We analyzed the incidence of alterations in the International Normalized Ratio (INR) and bleeding in cancer patients given minidose warfarin during treatment with continuous-infusion FU-based regimens...
  94. ncbi request reprint Isolated massive meningeal progression in aggressive non Hodgkin's lymphoma
    Massimo Magagnoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas Via Manzoni 56, 20089 Rozzano Milano Italy
    Haematologica 87:EIM15. 2002
  95. ncbi request reprint Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus
    Paolo Bidoli
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 94:352-61. 2002
    ..The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma...
  96. ncbi request reprint Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial
    Maurizio Infante
    Thoracic Surgery Department, Istituto Clinico Humanitas, Rozzano, Milano, Italy
    Lung Cancer 59:355-63. 2008
    ..We herewith present the baseline results of a randomized trial comparing screening for lung cancer with annual spiral computed tomography (CT) versus a yearly clinical review...
  97. ncbi request reprint Cardiac involvement in non-Hodgkin's lymphoma
    Massimo Magagnoli
    Department of Medical Oncology and Haematology, Department of Radiology, Istituto Clinico Humanitas, Rozzano Milan, Italy
    Br J Haematol 119:887. 2002
  98. doi request reprint Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy
    I Garassino
    Department of Oncology and Hematology, Istituto Clinico Humanitas IRCCS, 20089 Rozzano Milano, Italy
    Breast 18:263-6. 2009
    ....
  99. ncbi request reprint Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)
    H S Parra
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano Milano, Italy
    Cancer 92:650-6. 2001
    ..Therefore, the combined chemoimmunotherapy regimen is an worthwhile approach to evaluate in a Phase II trial...
  100. ncbi request reprint Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma
    M Magagnoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Bone Marrow Transplant 28:923-7. 2001
    ..These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs...